Shield Therapeutics Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BYV81293
GBP
0.11
0 (-1.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate -259.06% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.41
2

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 105 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

151.46%

stock-summary
Price to Book

-9.70

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
60.0%
0%
60.0%
6 Months
141.78%
0%
141.78%
1 Year
302.96%
0%
302.96%
2 Years
70.0%
0%
70.0%
3 Years
66.11%
0%
66.11%
4 Years
-68.0%
0%
-68.0%
5 Years
-78.85%
0%
-78.85%

Shield Therapeutics Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
22.70%
EBIT Growth (5y)
-259.06%
EBIT to Interest (avg)
-16.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-14.69
Sales to Capital Employed (avg)
0.73
Tax Ratio
2.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-7.40
EV to EBIT
-8.13
EV to EBITDA
-9.07
EV to Capital Employed
91.61
EV to Sales
2.87
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1127.52%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Shield Therapeutics Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 200.00% vs -85.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -105.08% vs -657.69% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.50",
          "val2": "1.50",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.00",
          "val2": "-18.20",
          "chgp": "-31.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-40.40",
          "val2": "-19.70",
          "chgp": "-105.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,911.30%",
          "val2": "-13,433.20%",
          "chgp": "752.19%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'22stock-summary

Dec'22
Dec'21
Change(%)
Net Sales
4.50
1.50
200.00%
Operating Profit (PBDIT) excl Other Income
-24.00
-18.20
-31.87%
Interest
0.40
0.00
Exceptional Items
-14.70
0.00
Consolidate Net Profit
-40.40
-19.70
-105.08%
Operating Profit Margin (Excl OI)
-5,911.30%
-13,433.20%
752.19%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 200.00% vs -85.58% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -105.08% vs -657.69% in Dec 2021

stock-summaryCompany CV
About Shield Therapeutics Plc stock-summary
stock-summary
Shield Therapeutics Plc
Pharmaceuticals & Biotechnology
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Company Coordinates stock-summary
Company Details
3rd Fl, Baltic Business Quarters, Abbott's Hill GATESHEAD None : NE8 3D
Registrar Details